Form 4: Terns Pharmaceuticals Director Radhika Tripuraneni Acquires Stock Options in Lieu of Cash Retainer

Radhika Tripuraneni, a director at Terns Pharmaceuticals, acquired stock options in lieu of a $40,000 cash retainer.

Summary

• Radhika Tripuraneni, a director of Terns Pharmaceuticals, received 10,657 stock options on February 1, 2025.
• These options were granted in place of a $40,000 cash retainer for the year 2025.
• The options have an exercise price of $4.46 per share.
• The options vest monthly starting January 1, 2025, with full vesting by January 1, 2026.
• The options expire on January 31, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between the director and the company. There are no negative implications.

Positives

• The director's decision to take stock options instead of cash demonstrates confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard practice for compensating board members, particularly in the biotech industry, where equity-based compensation is common to align director interests with shareholder value.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the pharmaceutical industry, especially for smaller companies where cash resources may be limited.
• The vesting schedule of 12 months is fairly standard for director stock options.
• The exercise price of $4.46 is a key metric, but without knowing the current market price of the stock, it's difficult to assess the value of the options.

Stakeholder Impact

• Shareholders may view this as a positive sign of director commitment.
• The use of stock options instead of cash may conserve company resources.

Key Dates

Keywords

stock options, director compensation, Terns Pharmaceuticals, insider trading, equity, Radhika Tripuraneni